Investor Relations

Latest Annual Filing

Fiscal Year Ended Dec 31, 2017

View Filing

Stock Information

Company Overview

AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus™, a CBD-based controlled release chewing gum containing 10mg of hemp-derived CBD, CanChew+ 50™, containing 50 mg of CBD undergoing clinical trials in patients with IBS, and MedChew Rx™, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy.

Corporate Presentation

Corporate Presentation

Download Corporate Presentation

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

AXIM Biotechnologies, Inc.
45 Rockefeller Plaza
20th Floor, Suite 83
New York, NY 10111
T: +1 212-751-0001

Investor Relations

T: 888-759-0844
Investors@aximbiotech.com

Transfer Agent

Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com

Close Menu